Elyse Watkins, DHSc, PA-C, DFAAPA
The treatment of heart failure with a reduced ejection fraction (HFrEF) continues to be an ongoing challenge faced by clinicians daily. For years, guideline-directed medical therapy (GDMT) has remained the same per the American Heart Association and American College of Cardiology. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a drug class that has long been recognized in treating patients with type 2 diabetes for their glucose-lowering effects. Emerging research now expands this drug class to nondiabetic patients with HFrEF. The objective of this article is to review the treatment of heart failure with a reduced ejection fraction (HFrEF) in nondiabetic patients with sodium-glucose cotransporter 2 (SGLT2) inhibitors and discuss the improved cardiovascular and renal outcomes, as measured by left ventricular (LV) remodeling, LV volume, LVEF, and estimated glomerular filtration rate (eGFR). The resultant quality of life (QoL) and functional capacity will also be examined. The new and detailed information will be valuable to practitioners because it can be conveyed and implemented into clinical practice. The expanded use of the SGLT2 inhibitors provides an alternative treatment option that can achieve positive outcomes like the other GMDT drug classes.
Olvera PL. The Novel Use of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Heart Failure. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.